Business
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid ReductionObserved
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid ReductionObserved Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose ReductionsFindings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult and pediatric patients achieved substantial reductions in glucocorticoid doses. These results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando.\n\n \n \n \n \n \n \n\n \nCongenital adrenal hyperplasia (CAH) is characterized by imbalances in hormone production, including cortisol, aldosterone and androgens, which cause a wide range of symptoms and can lead to long-term health problems.\n\"Historically, CAH has been treated with high-dose glucocorticoids alone. However, this approach can lead to serious and significant complications due to high-dose steroid use,\" said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. \"CRENESSITY, a novel oral corticotropin-releasing factor type 1 receptor antagonist, has demonstrated the potential to achieve two key therapeutic goals: reducing the effects of excess androgens and enabling reduction in glucocorticoid doses. This dual action may help reduce the adverse effects associated with chronic exposure to supraphysiologic doses of glucocorticoids.\" \nMore physiologic glucocorticoid (GC) treatment with greater reductions of androstenedione (A4) in pediatric patients (featured oral presentation): \nIn the CAHtalyst Pediatric study, children and adolescents with classic CAH (four to 17 years), including both salt-wasting and simple virilizing forms, were randomized to 28 weeks of double-blind treatment with placebo or CRENE...